Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo declines Lannett majority

This article was originally published in The Tan Sheet

Executive Summary

Perrigo announced it "has no present intention" to exercise its option to purchase a controlling interest in generic drug maker Lannett. "Unless circumstances change in a way that would increase the value of the Lannett acquisition to Perrigo," the move "would not be in the best long-term interest of our shareholders," CEO David Gibbons said June 10. Lannett said in a same-day statement that Perrigo's decision was motivated by concern over "possible increased acquisition costs resulting from the issuance of four million new shares of common stock in connection with Lannett's long-term distribution contract with Jerome Stevens Pharmaceuticals." Perrigo will continue to monitor developments at Lannett for the remainder of its option period, which ends Aug. 6, and remains committed to its strategy of entering the generic drug market...

Related Content

Perrigo Says Rx Generic Pursuits Will Strengthen OTC Private Label Business





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts